{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:50Z","timestamp":1791895430899,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00943-2","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:01:20Z","timestamp":1750442480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determinants of antibody levels and protection against omicron BQ.1\/XBB breakthrough infection"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-1976","authenticated-orcid":false,"given":"Carla","family":"Mart\u00edn P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ram\u00edrez-Morros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-8920","authenticated-orcid":false,"given":"Edwards","family":"Pradenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Canyelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-3404","authenticated-orcid":false,"given":"Roc\u00edo","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inocencia","family":"Cuamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-9874","authenticated-orcid":false,"given":"Luis","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-042X","authenticated-orcid":false,"given":"Benjamin","family":"Trinit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Vidal-Alaball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-6803","authenticated-orcid":false,"given":"Luis M.","family":"Molinos-Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0217","authenticated-orcid":false,"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-2326","authenticated-orcid":false,"given":"Anna","family":"Ruiz-Comellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-4060","authenticated-orcid":false,"given":"Carlota","family":"Doba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med.28, 1063 (2022).","journal-title":"Nat. Med."},{"key":"943_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"943_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","volume":"29","author":"JJ Lau","year":"2023","unstructured":"Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29, 348\u2013357 (2023).","journal-title":"Nat. Med."},{"key":"943_CR4","doi-asserted-by":"crossref","unstructured":"Arunachalam, P. S. et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J. Clin. Invest. 133, (2023).","DOI":"10.1172\/JCI167955"},{"key":"943_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"943_CR6","doi-asserted-by":"crossref","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 14, (2023).","DOI":"10.1038\/s41467-023-35815-7"},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 1\u201317 (2024).","journal-title":"Nat. Commun."},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1473-3099(22)00816-7","volume":"23","author":"R Uraki","year":"2023","unstructured":"Uraki, R. et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 23, 30\u201332 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"943_CR9","doi-asserted-by":"crossref","unstructured":"Qu, P. et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 42, (2023).","DOI":"10.1101\/2023.01.16.524244"},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","volume":"40","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D. et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 40, 306\u2013315 (2022).","journal-title":"Vaccine"},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"943_CR13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","volume":"28","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072\u20131082 (2022).","journal-title":"Nat. Med."},{"key":"943_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-024-03304-3","volume":"22","author":"C Mart\u00edn P\u00e9rez","year":"2024","unstructured":"Mart\u00edn P\u00e9rez, C. et al. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination. BMC Med. 22, 1\u201316 (2024).","journal-title":"BMC Med."},{"key":"943_CR15","doi-asserted-by":"publisher","first-page":"e2314757","DOI":"10.1001\/jamanetworkopen.2023.14757","volume":"6","author":"M Gilboa","year":"2023","unstructured":"Gilboa, M. et al. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel. JAMA Netw. Open 6, e2314757 (2023).","journal-title":"JAMA Netw. Open"},{"key":"943_CR16","doi-asserted-by":"publisher","first-page":"107621","DOI":"10.1016\/j.isci.2023.107621","volume":"26","author":"EAM Baerends","year":"2023","unstructured":"Baerends, E. A. M. et al. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection. iScience 26, 107621 (2023).","journal-title":"iScience"},{"key":"943_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38744-7","volume":"14","author":"J Perez-Saez","year":"2023","unstructured":"Perez-Saez, J. et al. Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1\/BA.2 infection. Nat. Commun. 14, 3032 (2023).","journal-title":"Nat. Commun."},{"key":"943_CR18","first-page":"1","volume":"14","author":"J Wei","year":"2023","unstructured":"Wei, J. et al. Protection against SARS-CoV-2 Omicron BA.4\/5 variant following booster vaccination or breakthrough infection in the UK. Nat. Commun. 14, 1\u201315 (2023).","journal-title":"Nat. Commun."},{"key":"943_CR19","doi-asserted-by":"crossref","unstructured":"St\u00e6rke, N. B. et al. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Nat. Commun. 13, (2022).","DOI":"10.1038\/s41467-022-32254-8"},{"key":"943_CR20","doi-asserted-by":"crossref","unstructured":"Santoro, A. et al. SARS-CoV-2 breakthrough infections according to the immune response elicited after mRNA third dose vaccination in COVID-19-Na\u00efve Hospital Personnel. Biomedicines 11, 1247.","DOI":"10.3390\/biomedicines11051247"},{"key":"943_CR21","doi-asserted-by":"crossref","unstructured":"Dimeglio, C. et al. Antibody titers and protection against omicron (BA.1 and BA.2) SARS-CoV-2 infection. Vaccines 10, 1548 (2022).","DOI":"10.3390\/vaccines10091548"},{"key":"943_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/vaccines12060564","volume":"12","author":"S Walmsley","year":"2024","unstructured":"Walmsley, S. et al. Declining levels of neutralizing antibodies to SARS-CoV-2 omicron variants are enhanced by hybrid immunity and original\/omicron bivalent vaccination. Vaccines (Basel) 12, 564 (2024).","journal-title":"Vaccines (Basel)"},{"key":"943_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/vaccines12010036","volume":"12","author":"S Walmsley","year":"2023","unstructured":"Walmsley, S. et al. Predictors of breakthrough SARS-CoV-2 infection after vaccination. Vaccines 12, 36 (2023).","journal-title":"Vaccines"},{"key":"943_CR24","doi-asserted-by":"crossref","unstructured":"Yamamoto, S. et al. Correlates of nucleocapsid antibodies and a combination of spike and nucleocapsid antibodies against protection of SARS-CoV-2 infection during the omicron XBB.1.16\/EG.5\u2013Predominant Wave. Open Forum Infect. Dis. 11, (2024).","DOI":"10.1093\/ofid\/ofae455"},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"126308","DOI":"10.1016\/j.vaccine.2024.126308","volume":"42","author":"M Canetti","year":"2024","unstructured":"Canetti, M. et al. Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers. Vaccine 42, 126308 (2024).","journal-title":"Vaccine"},{"key":"943_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227\u20131230 (2020).","journal-title":"Science"},{"key":"943_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1080\/22221751.2021.1913973","volume":"10","author":"A Rockstroh","year":"2021","unstructured":"Rockstroh, A. et al. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerg. Microbes Infect. 10, 774\u2013781 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"943_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/vaccines10020154","volume":"10","author":"R Guiomar","year":"2022","unstructured":"Guiomar, R. et al. Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. Vaccines ((Basel)) 10, 154 (2022).","journal-title":"Vaccines ((Basel))"},{"key":"943_CR29","doi-asserted-by":"crossref","unstructured":"Fu, J. et al. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 omicron variant in infection-na\u00efve and convalescent BNT162b2 recipients. Vaccines 10, (1904).","DOI":"10.3390\/vaccines10111904"},{"key":"943_CR30","doi-asserted-by":"crossref","unstructured":"Chowdhury, S. H. et al. Correlation of SARS-CoV-2 neutralization with antibody levels in vaccinated individuals. Viruses 15 (2023).","DOI":"10.3390\/v15030793"},{"key":"943_CR31","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/diagnostics12061315","volume":"12","author":"N Takheaw","year":"2022","unstructured":"Takheaw, N. et al. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination. Diagnostics 12, 1315 (2022).","journal-title":"Diagnostics"},{"key":"943_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.cell.2022.03.019","volume":"185","author":"V Servellita","year":"2022","unstructured":"Servellita, V. et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 185, 1539\u20131548.e5 (2022).","journal-title":"Cell"},{"key":"943_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.medj.2022.09.001","volume":"3","author":"ME Curlin","year":"2022","unstructured":"Curlin, M. E. et al. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. Med 3, 827\u2013837.e3 (2022).","journal-title":"Med"},{"key":"943_CR34","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3201\/eid3005.231739","volume":"30","author":"Y Lustig","year":"2024","unstructured":"Lustig, Y. et al. SARS-CoV-2 IgG levels as predictors of XBB variant neutralization, Israel, 2022 and 2023. Emerg. Infect. Dis. 30, 1050\u20131052 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"943_CR35","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/diagnostics12081781","volume":"12","author":"N Suntronwong","year":"2022","unstructured":"Suntronwong, N. et al. Strong correlations between the binding antibodies against wild-type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (Third-Dose) vaccination. Diagnostics 12, 1781 (2022).","journal-title":"Diagnostics"},{"key":"943_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556\u2013567 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"943_CR37","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg, Y. et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N. Engl. J. Med. 386, 2201\u20132212 (2022).","journal-title":"N. Engl. J. Med."},{"key":"943_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587\u2013599.e4 (2024).","journal-title":"Immunity"},{"key":"943_CR39","doi-asserted-by":"publisher","first-page":"103805","DOI":"10.1016\/j.ebiom.2021.103805","volume":"75","author":"G Moncunill","year":"2022","unstructured":"Moncunill, G. et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and na\u00efve healthcare workers. EBioMedicine 75, 103805 (2022).","journal-title":"EBioMedicine"},{"key":"943_CR40","doi-asserted-by":"publisher","unstructured":"Doba\u00f1o, C., Rubio, R., Maci\u00e0, D., Barrios, D. & Vidal, M. High-resolution kinetics and cellular determinants of antibody response to SARS-CoV-2 over two years after COVID-19 vaccination. https:\/\/doi.org\/10.21203\/RS.3.RS-3824689\/V1 (2024).","DOI":"10.21203\/RS.3.RS-3824689\/V1"},{"key":"943_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Effects of previous infection and vaccination on symptomatic omicron infections. N. Engl. J. Med. 387, 21\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"943_CR42","doi-asserted-by":"crossref","unstructured":"Doba\u00f1o, C. et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A, and G against SARS-CoV-2 antigens. J. Clin. Microbiol. 59, (2021).","DOI":"10.1128\/JCM.01731-20"},{"key":"943_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.trsl.2021.02.006","volume":"232","author":"C Doba\u00f1o","year":"2021","unstructured":"Doba\u00f1o, C. et al. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl. Res. 232, 60\u201374 (2021).","journal-title":"Transl. Res."},{"key":"943_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-24979-9","volume":"12","author":"N Ortega","year":"2021","unstructured":"Ortega, N. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat. Commun. 12, 1\u201310 (2021).","journal-title":"Nat. Commun."},{"key":"943_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/imm.13551","volume":"167","author":"C Doba\u00f1o","year":"2022","unstructured":"Doba\u00f1o, C. et al. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and na\u00efve primary health care workers upon COVID-19 vaccination. Immunology 167, 528\u2013543 (2022).","journal-title":"Immunology"},{"key":"943_CR46","doi-asserted-by":"crossref","unstructured":"Planchais, C. et al. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J. Exp. Med. 219, (2022).","DOI":"10.1101\/2022.04.01.486719"},{"key":"943_CR47","first-page":"313","volume":"2","author":"E Pradenas","year":"2021","unstructured":"Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N. Y) 2, 313\u2013320.e4 (2021).","journal-title":"Med (N. Y)"},{"key":"943_CR48","doi-asserted-by":"crossref","unstructured":"Doba\u00f1o, C. et al. Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain. BMC Med. 19, (2021).","DOI":"10.1186\/s12916-021-02184-1"},{"key":"943_CR49","doi-asserted-by":"crossref","unstructured":"Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8, (2023).","DOI":"10.1126\/sciimmunol.ade2798"},{"key":"943_CR50","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1126\/sciadv.adj9945","volume":"10","author":"N Lasrado","year":"2024","unstructured":"Lasrado, N. et al. Waning immunity and IgG4 responses following bivalent mRNA boosting. Sci. Adv. 10, 9945 (2024).","journal-title":"Sci. Adv."},{"key":"943_CR51","doi-asserted-by":"crossref","unstructured":"Mart\u00edn P\u00e9rez, C. et al. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections. J. Infect. 90, 106473 (2025).","DOI":"10.1016\/j.jinf.2025.106473"},{"key":"943_CR52","doi-asserted-by":"crossref","unstructured":"Richardson, S. I. et al. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. Cell Rep. Med. 4, (2023).","DOI":"10.1016\/j.xcrm.2022.100910"},{"key":"943_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"M Imai","year":"2023","unstructured":"Imai, M. et al. Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB. N. Engl. J. Med. 388, 89\u201391 (2023).","journal-title":"N. Engl. J. Med."},{"key":"943_CR54","doi-asserted-by":"crossref","unstructured":"van de Vyver, M. Immunology of chronic low-grade inflammation: relationship with metabolic function. J. Endocrinol. 257, (2023).","DOI":"10.1530\/JOE-22-0271"},{"key":"943_CR55","doi-asserted-by":"publisher","first-page":"15722","DOI":"10.3390\/ijms232415722","volume":"23","author":"G Pacinella","year":"2022","unstructured":"Pacinella, G., Ciaccio, A. M. & Tuttolomondo, A. Endothelial dysfunction and chronic inflammation: the cornerstones of vascular alterations in age-related diseases. Int J. Mol. Sci. 23, 15722 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"943_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser, R. Immune modulatory effects of statins. Immunology 154, 69 (2018).","journal-title":"Immunology"},{"key":"943_CR57","doi-asserted-by":"crossref","unstructured":"Patel, A. N., Varma, J. & Ganguly, B. Evidence of the immunomodulatory effects of selective serotonin reuptake inhibitors in patients with depression through a systematic review. Cureus 16, (2024).","DOI":"10.7759\/cureus.62991"},{"key":"943_CR58","doi-asserted-by":"crossref","unstructured":"Yang, H. S. et al. Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open 4, (2021).","DOI":"10.1001\/jamanetworkopen.2021.4302"},{"key":"943_CR59","doi-asserted-by":"crossref","unstructured":"Fraser, D. D. et al. Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon 9, (2023).","DOI":"10.1016\/j.heliyon.2022.e12704"},{"key":"943_CR60","unstructured":"Trigueros, M. et al. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. Age Ageing 51, (2022)."},{"key":"943_CR61","unstructured":"GISAID, via CoVariants.org. https:\/\/ourworldindata.org\/grapher\/covid-variants-area?time=2021-10-25..2023-09-11&facet=none&country=~ESP."},{"key":"943_CR62","unstructured":"Repositori de dades de recerca. https:\/\/dataverse.csuc.cat\/dataset.xhtml?persistentId=doi:10.34810\/data2205."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00943-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:01:25Z","timestamp":1750442485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00943-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00943-2","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: P. Santamaria is founder, scientific officer and stock holder of Parvus Therapeutics and receives funding from the company. He also has a consulting agreement with Sanofi. Carlota Doba\u00f1o is an Editorial Board Member for Communications Medicine, but was not involved in the editorial review or peer review, nor in the decision to publish this article. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}